GBG Forschungs GmbH (German Breast Group)

Validation of the MammaTyper (R) pathological complete response (pCR)-score as a predictor for response after neoadjuvant chemotherapy (NACT) in patients with early breast cancer (BC) (2018) Fasching P, Laible M, Weber KE, Wirtz RM, Denkert C, Schlombs K, Schmatloch S, et al. Conference contribution Germline mutation status and therapy response in patients with triple-negative breast cancer (TNBC): Results of the GeparOcto study (2018) Pohl E, Schneeweiss A, Hauke J, Moebus V, Furlanetto J, Denkert C, Fasching P, et al. Conference contribution Mutational diversity and therapy response in breast cancer-a sequencing analysis in the neoadjuvant GeparSepto trial (2018) Loibl S, Treue D, Budczies J, Weber K, Stenzinger A, Schmitt WD, Weichert W, et al. Conference contribution Outcome after neoadjuvant chemotherapy in elderly breast cancer patients - a pooled analysis of individual patient data from eight prospectively randomized controlled trials (2018) von Waldenfels G, Loibl S, Furlanetto J, Machleidt A, Lederer B, Denkert C, Hanusch C, et al. Journal article Outcome after neoadjuvant chemotherapy in estrogen receptor-positive and progesterone receptor-negative breast cancer patients: a pooled analysis of individual patient data from ten prospectively randomized controlled neoadjuvant trials (2018) Van Mackelenbergh MT, Denkert C, Nekljudova V, Karn T, Schem C, Marme F, Stickeler E, et al. Journal article BRCA1/2 Mutations and Bevacizumab in the Neoadjuvant Treatment of Breast Cancer: Response and Prognosis Results in Patients With Triple-Negative Breast Cancer From the GeparQuinto Study (2018) Fasching P, Loibl S, Hu C, Hart SN, Shimelis H, Moore R, Schem C, et al. Journal article Specific microRNA signatures in exosomes of triple-negative and HER2-positive breast cancer patients undergoing neoadjuvant therapy within the GeparSixto trial (2018) Stevic I, Mueller V, Weber K, Fasching P, Karn T, Marme F, Schem C, et al. Journal article Survival Analysis After Neoadjuvant Chemotherapy With Trastuzumab or Lapatinib in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in the GeparQuinto (G5) Study (GBG 44) (2018) Untch M, Von Minckwitz G, Gerber B, Schem C, Rezai M, Fasching P, Tesch H, et al. Journal article Treatment and outcomes of patients in the Brain Metastases in Breast Cancer Network Registry (2018) Witzel I, Laakmann E, Weide R, Neunhoeffer T, Park-Simon TJ, Schmidt M, Fasching P, et al. Journal article Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response-final results from GeparSixto (2018) Loibl S, Weber KE, Timms KM, Elkin EP, Hahnen E, Fasching P, Lederer B, et al. Journal article